Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,606 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-operative intervention Clear all
Terminated Phase 2 Interventional Results available

Metformin in Non Small Cell Lung Cancer (NSCLC)

NCT02285855
View directory record Official record
Conditions
Lung Cancer
Interventions
Metformin, Placebo, Stereotactic body Radiotherapy (SBRT)
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Spontaneous Pneumothorax in Children

NCT02573285
View directory record Official record
Conditions
Spontaneous Pneumothorax
Interventions
Simple Aspiration, Surgeon Preference
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 12, 2026, 7:30 PM EDT
Recruiting Not applicable Interventional

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

NCT06188585
View directory record Official record
Conditions
Acute Gastrointestinal Bleeding
Interventions
UI-EWD, Conventional therapy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 12, 2026, 7:30 PM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Phase 3 Interventional

Outcome of Different Ablation Strategies In Persistent and Long-Standing Persistent Atrial Fibrillation

NCT02533843
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
radiofrequency catheter ablation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

NCT00006233
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 12, 2026, 7:30 PM EDT
Withdrawn Phase 2 Interventional

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

NCT00723658
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 12, 2026, 7:30 PM EDT
Recruiting Phase 2 Interventional

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

NCT06160791
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytoses
Interventions
Ruxolitinib, Etoposide, Dexamethasone, Non-interventional Imaging, Research Biopsy, Biospecimen Collection
Drug · Procedure
Lead sponsor
Jerry Lee, MD, MSc, MPhil
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
Irvine, California • Sacramento, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Phase 4 Interventional

The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

NCT00995878
View directory record Official record
Conditions
Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
Focused ultrasound (MRgFUS), Uterine artery embolization (UAE)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 12, 2026, 7:30 PM EDT
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Innovative Concussion Prevention Device

NCT02901028
View directory record Official record
Conditions
Concussion
Interventions
Laboratory testing, Blood and Urine Draws
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Transversus Abdominis Plane Block

NCT06274307
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Transversus abdominis plane block
Procedure
Lead sponsor
Justin Hruska
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 12, 2026, 7:30 PM EDT
Recruiting Phase 3 Interventional

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

NCT05615844
View directory record Official record
Conditions
Open tíbia Fracture
Interventions
Antibiotic Cement Bead Pouch, Negative Pressure Wound Therapy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Chandler, Arizona • Tucson, Arizona • Davis, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 12, 2026, 7:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 12, 2026, 7:30 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers

NCT02838784
View directory record Official record
Conditions
Venous Ulcer, Foot Ulcer, Diabetic
Interventions
Artacent Human Amniotic Membrane, Standard of Care
Other · Procedure
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
7
States / cities
Arcadia, California • New Iberia, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 12, 2026, 7:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gene Expression Profiles in Multiple Sclerosis (MS)

NCT00704834
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood Draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

NCT00002521
View directory record Official record
Conditions
Lymphoma
Interventions
cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Temple University
Other
Eligibility
15 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 12, 2026, 7:30 PM EDT
Suspended Phase 1 Interventional

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT05993611
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 12, 2026, 7:30 PM EDT
Terminated Not applicable Interventional

Celecoxib in Treating Patients With Early-Stage Rectal Cancer

NCT00608595
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Phase 3 Interventional

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

NCT00004230
View directory record Official record
Conditions
Cancer
Interventions
captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 12, 2026, 7:30 PM EDT
Completed No phase listed Observational Results available

In Vivo Kinematics Comparison of Stryker or Zimmer Total Knee Arthroplasty

NCT01864434
View directory record Official record
Conditions
Knee Prosthesis
Interventions
Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA), Zimmer PCR TKA
Device
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
40 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 12, 2026, 7:30 PM EDT
Terminated Phase 2 Interventional Results available

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

NCT01532635
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
Radiation · Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 12, 2026, 7:30 PM EDT
Completed Not applicable Interventional Results available

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

NCT02162420
View directory record Official record
Conditions
Dyskeratosis Congenita, Aplastic Anemia
Interventions
Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, Anti-thymocyte globulin
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 12, 2026, 7:30 PM EDT
Terminated Not applicable Interventional

Observation Versus Immediate Surgery of Low Risk Bladder Cancer

NCT02700724
View directory record Official record
Conditions
Bladder Cancer
Interventions
Immediate Surgery, Observation, Surveillance Cystoscopy and Urinary Cytology
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 12, 2026, 7:30 PM EDT